Philippe Duclos

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. ncbi request reprint Safety of immunization and adverse events following vaccination against hepatitis B
    Philippe Duclos
    Immunization Safety Priority Project, Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    J Hepatol 39:S83-8. 2003
  2. doi request reprint National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening
    Philippe Duclos
    Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Ave Appia, CH 1211 Geneva 27, Switzerland
    Vaccine 28:A18-25. 2010
  3. ncbi request reprint Progress in the establishment and strengthening of national immunization technical advisory groups: analysis from the 2013 WHO/UNICEF joint reporting form, data for 2012
    Philippe Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva, Switzerland Electronic address
    Vaccine 31:5314-20. 2013
  4. doi request reprint Developing evidence-based immunization recommendations and GRADE
    P Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, 20 Ave Appia, CH 1211 Geneva 27, Switzerland
    Vaccine 31:12-9. 2012
  5. doi request reprint Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups
    Philippe Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, CH 1211 Geneva 27, Switzerland
    Vaccine 30:7147-52. 2012
  6. ncbi request reprint A global perspective on vaccine safety
    Philippe Duclos
    Immunization Safety Priority Project, Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Vaccine 22:2059-63. 2004
  7. doi request reprint Establishing global policy recommendations: the role of the Strategic Advisory Group of Experts on immunization
    Philippe Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Expert Rev Vaccines 10:163-73. 2011
  8. ncbi request reprint Immunization safety priority project at the World Health Organization
    Philippe Duclos
    Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization Geneva, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Semin Pediatr Infect Dis 14:233-9. 2003
  9. ncbi request reprint Safety of immunisation and adverse events following vaccination against hepatitis B
    Philippe Duclos
    Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, Geneva, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Expert Opin Drug Saf 2:225-31. 2003
  10. ncbi request reprint Invited commentary: pertussis, a forgotten killer
    Philippe Duclos
    Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Am J Epidemiol 155:897-8. 2002

Detail Information

Publications30

  1. ncbi request reprint Safety of immunization and adverse events following vaccination against hepatitis B
    Philippe Duclos
    Immunization Safety Priority Project, Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    J Hepatol 39:S83-8. 2003
  2. doi request reprint National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening
    Philippe Duclos
    Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Ave Appia, CH 1211 Geneva 27, Switzerland
    Vaccine 28:A18-25. 2010
    ....
  3. ncbi request reprint Progress in the establishment and strengthening of national immunization technical advisory groups: analysis from the 2013 WHO/UNICEF joint reporting form, data for 2012
    Philippe Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva, Switzerland Electronic address
    Vaccine 31:5314-20. 2013
    ..The GVAP represents a major opportunity to boost the institutionalization of NITAGs. A special approach needs to be explored to allow small countries to benefit from sub-regional or other countries advisory groups. ..
  4. doi request reprint Developing evidence-based immunization recommendations and GRADE
    P Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, 20 Ave Appia, CH 1211 Geneva 27, Switzerland
    Vaccine 31:12-9. 2012
    ..Ongoing utilisation should result in further fine-tuning of the approach to ensure that recommendations are based on the full range of appropriate evidence...
  5. doi request reprint Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups
    Philippe Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, CH 1211 Geneva 27, Switzerland
    Vaccine 30:7147-52. 2012
    ..Some of the poorest developing countries now enjoy support from a NITAG which meet all six process indicators. These may serve as examples for other countries...
  6. ncbi request reprint A global perspective on vaccine safety
    Philippe Duclos
    Immunization Safety Priority Project, Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Vaccine 22:2059-63. 2004
    ....
  7. doi request reprint Establishing global policy recommendations: the role of the Strategic Advisory Group of Experts on immunization
    Philippe Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Expert Rev Vaccines 10:163-73. 2011
    ..WHO vaccine-related recommendations have become a necessary step in the pathway to the introduction and use of vaccines, especially in developing countries and, consequently, have a clear and significant impact...
  8. ncbi request reprint Immunization safety priority project at the World Health Organization
    Philippe Duclos
    Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization Geneva, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Semin Pediatr Infect Dis 14:233-9. 2003
    ..The project emphasizes the importance of advocating safety and building capacity at national levels...
  9. ncbi request reprint Safety of immunisation and adverse events following vaccination against hepatitis B
    Philippe Duclos
    Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, Geneva, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Expert Opin Drug Saf 2:225-31. 2003
    ..The risks of hepatitis B vaccination are only theoretical in comparison with clear benefits in terms of cirrhosis and cancer prevention, and the HBV remains one with an excellent safety profile...
  10. ncbi request reprint Invited commentary: pertussis, a forgotten killer
    Philippe Duclos
    Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Am J Epidemiol 155:897-8. 2002
  11. ncbi request reprint Immunisation safety: a priority of the World Health Organization's Department of Vaccines and Biologicals
    P Duclos
    Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, Geneva, Switzerland
    Drug Saf 24:1105-12. 2001
    ..The project emphasises the importance of advocating safety and developing necessary infrastructure and human resource to properly deal with immunisation related safety issues at a national level...
  12. ncbi request reprint [Global immunization policies and recommendations: objectives and process]
    Philippe Duclos
    Immunization, Vaccines and Biologicals, World Health Organization, 20, Avenue Appia, CH 1211 Geneva 27, Suisse
    Med Sci (Paris) 23:409-16. 2007
    ..This includes the Strategic Advisory Group of Experts, the Global Advisory Committee on Vaccine Safety and the Expert Committee on Biological Standardization. The elaboration of WHO vaccine position papers is also described...
  13. doi request reprint Consultation on interactions between National Regulatory Authorities and National Immunization Technical Advisory Groups
    Liliana Chocarro
    World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Expert Rev Vaccines 10:1265-70. 2011
    ....
  14. doi request reprint Sustaining GAVI-supported vaccine introductions in resource-poor countries
    Patrick L F Zuber
    Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Av Appia, 1211 Geneva, Switzerland
    Vaccine 29:3149-54. 2011
    ....
  15. ncbi request reprint The global burden of measles in the year 2000--a model that uses country-specific indicators
    Claudia E Stein
    Global Programme on Evidence for Health Policy, World Health Organization, Geneva, Switzerland
    J Infect Dis 187:S8-14. 2003
    ..This approach quantifies the measles burden by considering country-specific indicators, which can be updated, permitting an assessment of country, regional, and global changes in the burden associated with measles infection...
  16. ncbi request reprint Ensuring vaccine safety in immunization programmes--a WHO perspective
    L Jodar
    Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, 20 Avenue Appia, 1211 27, Geneva, Switzerland
    Vaccine 19:1594-605. 2001
    ..Above all, there is a willingness to respond to new climates and new technologies so that the Organization is in the best position to ensure safe immunization for all the world's children...
  17. ncbi request reprint Injection practices in Burkina Faso in 2000
    J Fitzner
    World Health Organization Headquarters, Geneva, Switzerland
    Int J Qual Health Care 16:303-8. 2004
    ..Unsafe delivery and overuse of injections can result in the spread of hepatitis B virus, hepatitis C virus, and HIV. The aim of the present survey was to estimate the frequency of safe injection practices in Burkina Faso...
  18. ncbi request reprint Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso
    Adwoa D Bentsi-Enchill
    World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Vaccine 25:A72-8. 2007
    ..The findings confirm the benefits of the vaccine in the control of meningococcal meningitis...
  19. ncbi request reprint Improved injection safety after targeted interventions in the Syrian Arab Republic
    Carsten Mantel
    Institute of Tropical Medicine and International Health, Charite Universitatsmedizin Berlin, Germany
    Trop Med Int Health 12:422-30. 2007
    ..A follow-up survey was carried out in February 2004, 2 years after initiation of the project...
  20. ncbi request reprint The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)
    Jan Bonhoeffer
    University Children s Hospital Basel, Basel, Switzerland
    Vaccine 21:298-302. 2002
    ..Comparability requires the availability of standardized case definitions for adverse events following immunization (AEFI) and guidelines for case determination, recording and data presentation...
  21. ncbi request reprint Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues
    Robert P Pless
    National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 187:S291-8. 2003
    ..The implementation of safety surveillance for mass campaigns offers a unique opportunity for countries to avoid crisis situations and to begin vaccine safety monitoring in routine immunization programs...
  22. ncbi request reprint The Brighton Collaboration-enhancing vaccine safety
    Jan Bonhoeffer
    Division of Pediatrics Infectious Diseases and Vaccines, University Children s Hospital, P O Box 8, 4005 Basel, Switzerland
    Vaccine 22:2046. 2004
  23. ncbi request reprint Improving global monitoring of vaccine safety: a survey of national centres participating in the WHO Programme for International Drug Monitoring
    Megan Letourneau
    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada
    Drug Saf 31:389-98. 2008
    ....
  24. ncbi request reprint The development of standardized case definitions and guidelines for adverse events following immunization
    Katrin S Kohl
    Vaccine 25:5671-4. 2007
  25. ncbi request reprint Vaccine safety controversies and the future of vaccination programs
    Guido François
    Viral Hepatitis Prevention Board, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerpen, Antwerp, Belgium
    Pediatr Infect Dis J 24:953-61. 2005
    ....
  26. ncbi request reprint Standardized case definitions of adverse events following immunization (AEFI)
    Jan Bonhoeffer
    Vaccine 22:547-50. 2004
  27. ncbi request reprint The Brighton Collaboration: enhancing comparability of vaccine safety data
    Katrin S Kohl
    Centers for Disease Control and Prevention, National Immunization Program, 1600 Clifton Rd, Mailstop E 61, Atlanta, GA 30333, USA
    Pharmacoepidemiol Drug Saf 12:335-40. 2003
  28. doi request reprint Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database
    Megan Letourneau
    Department of Epidemiology and Community Medicine, University of Ottawa, 451Smyth Road, Ottawa, ON, Canada K1H 8M5
    Vaccine 26:1185-94. 2008
    ....
  29. ncbi request reprint Unsterile injections and emergence of human pathogens
    Yvan J F Hutin
    Lancet 359:2280. 2002